Hyperthermic intracavitary nanoaerosol therapy (HINAT) as an improved approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC): Technical description, experimental validation and first proof of concept

• Daniel Göhler,
• Stephan Große,
• Alexander Bellendorf,
• Thomas Albert Falkenstein,
• Mehdi Ouaissi,
• Jürgen Zieren,
• Michael Stintz and
• Urs Giger-Pabst

Beilstein J. Nanotechnol. 2017, 8, 2729–2740, doi:10.3762/bjnano.8.272

• chemotherapy for the treatment of peritoneal carcinomatosis. However, recent reports reveal limitations of the currently available technology. Material and Methods: A novel approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC), called hyperthermic intracavitary nanoaerosol therapy (HINAT

• nm) unipolar-charged hyperthermic (41 °C) drug aerosol for quasi uniform drug deposition over the whole peritoneum with significantly deeper drug penetration than that offered by conventional PIPAC. Keywords: HINAT; intracavitary; intraperitoneal; nanoaerosol; PIPAC; pressurized; therapy

• substances at minimal systemic toxicity, first approaches for locoregional/intracavitary chemotherapy (ICC) based on liquid drug instillation (LICC) were already developed about forty years ago [2][3][4]. Unfortunately, the effectivity of LICC is limited by low in-tissue penetration and the difficulties to